Welcome to our dedicated page for CBD.U news (Ticker: CBD.U), a resource for investors and traders seeking the latest updates and insights on CBD.U stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CBD.U's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CBD.U's position in the market.
HempFusion Wellness Inc. (TSX:CBD.U) announced the completion of a pilot study with the Inflammatory Markers Laboratory, demonstrating that its CBD Capsules® may significantly reduce thromboxane production, a marker linked to inflammation. The results indicate potential benefits in managing chronic inflammation and have led to the creation of a white paper titled “Oral Formulation May Modulate Thromboxane Production.” The study, co-authored by notable experts, reflects HempFusion's commitment to research in hemp-derived CBD and its safe, effective applications. The company also sponsors one of the largest CBD toxicology studies.
HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) announced initial findings from a large observational liver toxicology study on hemp-derived CBD products. Conducted by Validcare, the study showed no evidence of liver toxicity among the 839 participants. The FDA was briefed on these findings, which aim to inform safe regulatory pathways for CBD products. The study's success has led to the addition of a second cohort for increased statistical certainty. The results are seen as a pivotal step forward for the CBD industry, validating HempFusion's commitment to consumer safety.
HempFusion Wellness Inc. (TSX:CBD.U) (US:CBDHF) announces the launch of Probulin products on Alibaba's Tmall Global, expanding its market reach to over 750 million consumers in Asia. The expected availability starts March 29, 2021, coinciding with the significant 618 shopping festival in China, which saw USD$98.52 billion in sales last year. This marks a pivotal moment in HempFusion’s growth strategy, as it aims to leverage Tmall’s vast consumer engagement opportunities, including influencer marketing, to educate the market about its probiotic benefits.
HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) announces its OTC Topical Products have achieved the highest rank in sales dollars and units sold at a major Food & Drug Mass retailer, as reported by NielsenIQ. This milestone reflects the company’s commitment to regulatory compliance and high-quality product development. The Food & Drug Mass channel is identified as a key growth opportunity, with an anticipated increase in consumer purchasing of CBD products. HempFusion aims to expand its distribution across additional major retailers in the U.S. and globally.
HempFusion Wellness has submitted a novel foods application to the UK's Regulatory Food Safety Agency (FSA) as part of the regulatory approval process for CBD products. This comprehensive submission includes toxicology data and details on the quality and safety of HempFusion's ingredients. The application is seen as essential to the company's growth in the UK market and in anticipation of EU regulations. HempFusion emphasizes its commitment to regulatory compliance and consumer safety through ongoing studies, including participation in ValidCare’s significant human observational study.
HempFusion Wellness Inc. (TSX:CBD.U, OTCQX:CBDHF) announced its common shares received DTC full-service eligibility, allowing trading through DTC's electronic system in the U.S. This approval will enhance liquidity and attract a broader range of investors, including online trading platforms and brokerage firms. The company's product portfolio includes 48 SKUs of CBD products and 30 additional products under development.
HempFusion Wellness announced its exclusive CBD brand selection by Mount Sinai Medical Hospital for a six-month clinical trial. Conducted by Dr. David Harnick, this trial aims to evaluate CBD's impact on cardiology markers and deepen understanding of its effects. Commencing in March 2021, it represents significant research in CBD's health benefits, as no prior controlled studies exist on this topic. HempFusion’s CBD products will also be part of the ValidCare observational studies focused on liver and reproductive health.
HempFusion Wellness has expanded its product line to 48 SKUs with new Sleep and Stress products featuring twice the CBD per serving, now at 300 mg. The company aims to cater to the increasing demand for higher CBD concentrations among consumers. The products, containing GABA and ASHWAGANDHA, are designed to support relaxation and ease stress while remaining THC-free. Available on their website, these innovations reflect HempFusion's commitment to providing sought-after health solutions in the CBD market.
HempFusion Wellness announced that Ms. Ola Lessard has been elected for a second consecutive term as President of the U.S. Hemp Roundtable. This historic election marks her as the first woman and two-term president in the organization’s history. The U.S. Hemp Roundtable advocates for national hemp legislation and comprises leading companies in the hemp industry. HempFusion has been a member for over two years and aims to achieve clarity for CBD as a dietary supplement. Lessard's leadership is expected to enhance HempFusion's insights into regulatory developments.
HempFusion Wellness Inc. (TSX:CBD.U) (OTC Pink:CBDHF) has secured its OTC Markets trading symbol 'CBDHF', enhancing access for U.S. investors. CEO Jason Mitchell emphasized that this step broadens investor reach and is coupled with an application for OTCQX listing and DTC eligibility, pending approval. The company markets a diverse range of whole-food hemp nutrition products across approximately 4,000 retail locations in the U.S. and internationally, featuring 46 SKUs and an additional 30 products in development.
